Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

$5.14 +0.16 (+3.21%)

(As of 12/20/2024 05:16 PM ET)

Foghorn Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 5 Analyst Ratings

Sell
0

Hold
1

Buy
4

Based on 5 Wall Street analysts who have issued ratings for Foghorn Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 1 has given a hold rating, and 4 have given a buy rating for FHTX.

Consensus Price Target

$13.80
168.48% Upside

According to the 5 analysts' twelve-month price targets for Foghorn Therapeutics, the average price target is $13.80. The highest price target for FHTX is $20.00, while the lowest price target for FHTX is $9.00. The average price target represents a forecasted upside of 168.48% from the current price of $5.14.

Get the Latest News and Ratings for FHTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Foghorn Therapeutics and its competitors.

FHTX Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$13.80	$16.00	$15.40	$14.83
Forecasted Upside	168.48% Upside	106.04% Upside	54.15% Upside	120.73% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis (Ad)

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

FHTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

FHTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Foghorn Therapeutics Stock vs. The Competition

Type	Foghorn Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	168.48% Upside	25,828.57% Upside	14.53% Upside
News Sentiment Rating	Neutral News See Recent FHTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/17/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $13.00	+135.93%
12/16/2024	Jefferies Financial Group 2 of 5 stars		Lower Target	Buy ➝ Buy	$18.00 ➝ $14.00	+179.44%
9/24/2024	Morgan Stanley 3 of 5 stars		Boost Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $9.00	-3.43%
8/19/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Clark-Gartner Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00	+219.49%
8/8/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$13.00 ➝ $13.00	+148.09%
6/28/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$21.00 ➝ $19.00	+120.93%
4/25/2023	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$20.00 ➝ $19.00	+206.95%
3/28/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$10.00	+108.77%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:53 PM ET.

FHTX Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Foghorn Therapeutics is $13.80, with a high forecast of $20.00 and a low forecast of $9.00.
: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Foghorn Therapeutics in the last year. There is currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FHTX shares.
: According to analysts, Foghorn Therapeutics's stock has a predicted upside of 168.48% based on their 12-month stock forecasts.
: Foghorn Therapeutics has been rated by research analysts at HC Wainwright, Jefferies Financial Group, and Morgan Stanley in the past 90 days.
: Analysts like Foghorn Therapeutics less than other "medical" companies. The consensus rating score for Foghorn Therapeutics is 2.80 while the average consensus rating score for "medical" companies is 2.81. Learn more on how FHTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis (Ad)

Find out details on these three critical Nvidia partners immediately.

This page (NASDAQ:FHTX) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Foghorn Therapeutics (FHTX) Stock Forecast & Price Target